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Summary
Mutations in the von Hippel-Lindau (VHL) gene are associated with hereditary and sporadic clear cell renal carcinoma.
VHL acts in a ubiquitin ligase complex regulating hypoxia-inducible factor-1 (HIF-1), but the link between this function and
cancer development is unclear. Here we show that in the kidneys of patients with VHL disease, HIF activation is an early
event occurring in morphologically normal single cells within the renal tubules. In comparison, dysplastic lesions, cystic
lesions, and tumors showed evidence of additional mechanisms that amplify HIF activation. Detection of cells with constitu-
tive HIF activation identified a large number of previously unrecognized foci of VHL inactivation. In proximal tubules these
were almost entirely unicellular, whereas multicellular foci were almost exclusively seen in the distal nephron.
Introduction rial into fully transformed cells. Thus, reintroduction of a wild-
type VHL gene into transformed tissue culture cells has been
Tumor suppressor genes isolated by studying kindreds with shown to influence several aspects of cellular behavior that may
familial cancer syndromes have given valuable insights into car- be relevant to tumor suppressor function (for review see Kondo
and Kaelin, 2001). Specifically, VHL defective renal carcinomacinogenesis (Knudson, 2000). One such tumor suppressor gene
is VHL, mutations in which give rise to von Hippel-Lindau dis- cell lines exhibit failure to degrade hypoxia inducible factor (HIF)
 subunits in the presence of oxygen (Maxwell et al., 1999) andease (Kondo and Kaelin, 2001; Latif et al., 1993). Affected indi-
viduals have a lifetime risk of developing renal cell carcinoma failure to assemble a fibronectin matrix (Ohh et al., 1998), and
under certain conditions fail to exit from the cell cycle or showthat is in the region of 70%, with the tumors showing somatic
loss or inactivation of the second allele. In accordance with increased susceptibility to apoptosis (Pause et al., 1998;
Schoenfeld et al., 2000). All these abnormalities in monolayerKnudson’s two-hit hypothesis, sporadic clear cell renal cell car-
cinomas (CCRCC) show mutation or loss of the VHL gene in cultures can be corrected by transfection with a wild-type VHL
gene.the great majority of cases (Foster et al., 1994; Gnarra et al.,
1994). However, the mechanism(s) underlying this pivotal role Though these experiments provide clear evidence of spe-
cific VHL functions in a fully transformed cell background, theyin CCRCC remains incompletely understood.
Key insights into VHL function have come from the classical cannot address important questions about the timing and con-
sequences of tumor suppressor inactivation during progressionapproach of studying the effects of reintroducing genetic mate-
S I G N I F I C A N C E
Since cancer development is a multistep process, the effects of tumor suppressor inactivation must be considered against an
accruing background of genetic change that may affect assays of function. The current work exemplifies this for one such property
of a tumor suppressor, regulation of HIF by the VHL gene product. The study defines both early and progressive upregulation of the
HIF pathway following VHL inactivation, implicating HIF activation in both early and later stages of VHL associated tumorigenesis.
Furthermore, identification and analysis of very early lesions showed that they promote angiogenesis, and that effects of VHL
inactivation on proliferation are site specific within the nephron. This provides a focus for understanding VHL tumor suppressor function
in kidney cells.
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from a normal cellular phenotype to overt carcinoma. In other tubules. As expected from previous studies of sporadic tumors
(Liao et al., 1997; Wykoff et al., 2000), overt CCRCC labeledtypes of cancer, DNA studies have demonstrated inactivation
of tumor suppressors such as APC at an early stage in carcino- intensely for CAIX (Figure 1A). A high level of CAIX was also
expressed by the epithelial cells lining the benign cystic lesionsgenesis, but such studies have necessarily centered on cells
that have already become morphologically abnormal (Kinzler characteristic of VHL disease (Motzer et al., 1996) (Figure 1B).
In addition, focal sites of CAIX expression scattered throughoutand Vogelstein, 1996; Shih et al., 2001). Other strategies for
analyzing early events in cancer development have focused on the larger mass of CAIX-negative renal parenchyma were ob-
served (Figures 1C–1H). Some of these regions exhibited dis-induced gene expression or gene inactivation in animal models
(Hakem and Mak, 2001; Hanahan and Folkman, 1996; Wu and torted or cystic tubular architecture, and in some there was
evidence of non-monolayer growth since the cells were not allPandolfi, 2001). Overall, there is a paucity of markers that permit
analysis of events in human cancers from the first changes in in direct contact with the basement membrane (Figure 1H).
Intriguingly, however, most foci of CAIX-positive epithelial cellsmorphologically normal cells (Porter, 2001). In an effort to ad-
dress this problem, we sought to study activation of the HIF were identified in apparently normal tubules (Figures 1C–1F). In
each patient, CAIX-positive cells were most often seen as singlesystem during the development of VHL-associated CCRCC.
VHL acts as the recognition component of a multiprotein tubular cells (Figures 1C–1E), although multicellular foci were
also observed (Figures 1F–1H). In the material examined, weE3 ubiquitin ligase complex, capturing HIF- chains which have
undergone oxygen-regulated hydroxylation of specific prolyl observed 545 foci of CAIX expression. We examined adjacent
sections stained with hematoxylin and eosin for morphologicalresidues and resulting in their ubiquitylation and destruction
(Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., abnormalities (for example, cystic change or distortion of the
tubular structure), which would be differentiated from normal2001; Jaakkola et al., 2001; Yu et al., 2001). In renal carcinoma
cells lacking functional VHL, HIF- subunits accumulate even renal parenchyma by routine histological evaluation. Only 21
such regions were readily discernible, each of which corre-in the presence of oxygen and form a transcriptionally active
complex that directs the expression of a constitutive hypoxia- sponded to a multicellular focus of CAIX labeling.
In contrast to our finding of numerous foci labeling for CAIXlike pattern of gene expression (Maxwell et al., 1999). Since
HIF targets include angiogenic growth factors, and successful in this material, 20 nephrectomy specimens from patients with
sporadic CCRCC, or sporadic renal tumors of other histologicalangiogenesis is a key step in tumor development beyond a size
of approximately 1 mm3 (Hanahan and Folkman, 1996), it seems types, did not contain any such foci of CAIX-positive epithelial
cells in the kidney around the tumor (data not shown).likely that HIF activation contributes to later stages of VHL-
associated tumorigenesis. To date, however, it has not been To confirm that the foci of CAIX expression represented
activation of the HIF pathway, we examined expression of twoestablished whether activation of the HIF transcriptional cas-
cade is an early consequence of VHL loss-of-function in normal other HIF-responsive genes encoding the glucose transporter
GLUT-1 (Ebert et al., 1995) and the angiogenic growth factormammalian cells, or whether this only happens after other
events occur during the evolution of renal carcinoma. VEGF (Iyer et al., 1997). Immunolabeling for GLUT-1 revealed
high levels in overt CCRCC, and also in collections of cells inWe reasoned that evaluating the HIF system in kidneys from
patients with VHL disease would address important issues con- the nontumorous renal parenchyma that resembled the CAIX
expressing foci. As expected for a gene whose expression iscerning the timing and consequences of dysregulation of this
pathway. Tumor-associated nephrectomy specimens from VHL also regulated by other pathways (Ebert et al., 1995; Hiraki et
al., 1988), GLUT-1 expression was somewhat less restrictedpatients were therefore analyzed for evidence of activation of
the HIF system. Stabilization of HIF- subunits was studied than CAIX, being present in erythrocytes, in a small subset of
glomerular cells, and occasionally in collecting ducts, whereusing isoform-specific antibodies for HIF-1 and HIF-2. HIF
transcriptional activity was assessed by examining expression CAIX labeling was virtually never observed (see below). How-
ever, examination of serial sections confirmed that the bound-of selected target genes involved in different cellular processes:
carbonic anhydrase 9 (CA9) (Ivanov et al., 1998; Wykoff et al., aries of the CAIX-positive early lesions corresponded exactly
to those of the GLUT-1 expressing foci, as would be anticipated2000), VEGF (Iyer et al., 1997), and GLUT-1 (Ebert et al., 1995).
if these foci represent cells manifesting mutational activation of
the HIF/VHL pathway (Figure 2A). As a third marker of HIFResults
activation, VEGF expression was analyzed. In contrast to
GLUT-1 and CAIX, which are transmembrane proteins, VEGFHIF activation in early VHL-associated lesions
To detect activation of the HIF pathway, we first immunolabeled is secreted, and was therefore studied using in situ mRNA hy-
bridization. As reported previously in normal kidney, VEGF ex-sections for the HIF target carbonic anhydrase IX (CAIX) using
the monoclonal antibody M75 (Pastorekova et al., 1992), which pression was less restricted than CAIX, being prominent in glo-
merular epithelial cells (Brown et al., 1992). However, discretehas been extensively validated for detection of this protein. Expres-
sion of the CA9 gene is regulated by the VHL/HIF system via a foci of abnormally high VEGF expression were clearly evident
in some tubules, and in adjacent sections these were preciselyHIF responsive element in the promoter, and its protein product,
CAIX, constitutes an attractive marker for HIF activation because concordant with foci of CAIX expression (Figure 2B). These
lesions therefore coexpress three independent HIF target genesthe inducible response is of particularly high amplitude and the
protein is very stable (Ivanov et al., 1998; Wykoff et al., 2000). that are involved in different cellular processes.
To investigate the VHL status of these lesions, we first la-Eleven nephrectomy specimens from 10 patients with VHL
disease were labeled with CAIX antibody. The material in each beled sections with a monoclonal antibody to VHL, IG33. In the
normal renal parenchyma, this antibody labeled collecting, distalcase included overt CCRCC and apparently normal renal paren-
chyma. In some cases there were also cysts and dysplastic and proximal tubules, with stronger signal () in the distal
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Figure 1. CAIX immunoreactivity in kidneys of VHL patients
A: A region of overt CCRCC showing labeling of all cells (final magnification 50).
B: The wall of a cyst, showing labeling of flattened epithelial cells lining the cyst (360).
C and D: Morphologically normal regions showing CAIX expression in single epithelial cells (360).
E: Low magnification view including a number of isolated tubular cells expressing CAIX (110). Inset shows one of these single cellular foci (360).
F: A tubular profile in which the majority of the lumen is lined by cells expressing CAIX (360).
G: Distorted tubular profile showing an extensive region of CAIX labeling (240).
H: A tubular profile containing a region of dysplasia which expresses CAIX (300).
tubules. Comparison of the IG33 staining with the CAIX staining ing any need for cross-comparison of different tubular profiles.
Since IG33 recognizes the N-terminal portion of VHL that isin serial sections revealed that there was a striking diminution,
or loss, of VHL immunoreactivity which corresponded precisely unnecessary for tumor suppressor function (Iliopoulos et al.,
1998; Schoenfeld et al., 1998), the sharply reduced (but notwith regions of CAIX positivity (Figure 2A). In particular, this
pattern of overlap was evident in numerous foci where the CAIX- absent) staining probably represents persisting expression of
functionally inactive mutant protein that retains this epitope.positive cells constituted only part of the tubular profile, eliminat-
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Figure 2. Expression of HIF target genes and analysis of VHL status in foci of HIF activation
Sections were labeled with antibodies or hybridized with riboprobes to VEGF as indicated.
A: A single tubular profile showing cells that express CAIX and cells that do not. The region labeled for CAIX shows a high level of expression of GLUT-1. In
this portion of the distal tubular profile, a marked reduction in labeling for VHL is seen (from  to ), with the boundary corresponding precisely to the
boundary of the CAIX immunolabeled region. Arrows indicate this boundary. Note that labeling for VHL is more intense () in the distal tubular profiles
than in the proximal tubules (top of field, ), a small vessel, and interstitial cells ().
B: Three tubular profiles are seen in which the epithelial cells are immunoreactive for CAIX. In situ hybridization of an adjacent section shows a high level
of VEGF mRNA in these cells (dark field view). Hybridization to a sense probe as a control indicates that the signal is specific.
C: Laser capture microdissection and PCR allelotyping. A tubular profile containing an early focus was identified by CAIX immunolabeling (left panel). This
focus was captured using laser microdissection (center panel). The right panel shows the allelotype at D3S1038 of this early lesion (upper trace) and from
a group of cells which were negative for CAIX and were captured from the same section. The wild-type allele is lost in the early lesion.
(Final magnification: A: 300; B: 210; C: 300).
In further experiments, we used an antibody that recognizes demonstrated in the region of the VHL gene (Figure 2C). In two
of these patients (three foci) it was possible to establish whichthe C terminus of VHL, A1.2 (Schoenfeld et al., 1998), and also
undertook DNA analysis of the VHL locus. When we labeled marker allele was linked to the mutant VHL allele, and in each
instance, the marker allele linked to the wild-type VHL allelecontrol kidneys and VHL kidneys with A1.2, we observed signal
in a tightly restricted portion of the nephron, being essentially was lost in the foci. Taken together, the immunolabeling and
DNA analysis demonstrate that the CAIX-positive foci harbor aconfined to the collecting tubule, collecting duct, and a subset
of distal tubular profiles, suggesting that labeling with this anti- defect in the normal VHL allele.
The regulatory HIF- subunits exist as two main isoformsbody is less sensitive than with IG33. Consequently, A1.2 immu-
nolabeling was only informative concerning VHL expression in that are controlled by VHL-mediated proteolysis, HIF-1 and
HIF-2 (Maxwell et al., 1999). To analyze the characteristics ofa subset of lesions. In this subset, CAIX-expressing cells that
occupied part of the tubular perimeter showed complete loss HIF activation in the different lesions, we next labeled sections
using specific antibodies for each isoform. In the normal renalof A1.2 immunoreactivity when compared to their neighbors
(data not shown). parenchyma of VHL patients, clearly demarcated foci of HIF-
1 staining were observed, both in proximal and in distal tubularIn another approach, we used laser capture dissection to
isolate small multicellular foci and analyzed markers linked to cells. Analysis of serial sections showed that these foci of HIF-
1 expression were precisely concordant with the CAIX-positivethe VHL gene by PCR. Amplification was successful in a total
of seven samples from four different nephrectomy specimens; early lesions (Figure 3A). Comparison of different foci on the
same section revealed that while HIF-1 labeling was only ofin each case, 3p25 allele loss (at D3S1317 or D3S1038) was
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Figure 3. Labeling for individual HIF- subunits in foci of HIF activation
Adjacent sections or defined sections from a series were labeled with antibodies as indicated.
A: A tubule in which epithelial cells express CAIX. The tubule shows clear but weak nuclear labeling () for HIF-1. HIF-2 was virtually undetectable.
B: A distorted tubular structure. Immunoreactive cells for CAIX show nuclear labeling for both HIF-1 and HIF-2 ().
C: A cyst lined by cells expressing high levels of CAIX. These cells show moderate staining for both HIF-1 and HIF-2 ().
(Final magnification: A: 300; B and C: 180).
weak intensity () in the earliest lesions, it was further upregu- we selected 29 multicellular CAIX-positive foci which occupied
part of a tubular profile, and examined cellular morphology inlated () in more advanced lesions, with labeling being consis-
tently more intense in the epithelium lining cystic lesions, and the adjacent sections stained with hematoxylin and eosin. In
only 6 of these foci could we discern any alteration in nuclearin overt CCRCC (), than in the earlier foci (Figures 3A–3C,
and data not shown). In contrast to the findings for HIF-1, morphology, nuclear to cytoplasmic ratio, or tubular architec-
ture. However, in the majority of foci (19/29), the cytoplasmwe detected virtually no HIF-2 immunoreactivity in the CAIX-
positive foci that were morphologically normal or near normal of CAIX-positive cells in early lesions exhibited a “clear cell”
appearance (Figure 4A). That we observed this feature reminis-(Figure 3A). HIF-2 was detected at weak intensity () in the
small subset of foci where the tubular and/or cellular morphol- cent of overt CCRCC (Motzer et al., 1996) in many of the early
lesions suggests that, like HIF activation, it occurs at a veryogy was abnormal (Figure 3B), with more intense signal in cysts
(, Figure 3C) and in regions of overt CCRCC () (data early stage in tumor development.
Morphological examination of the early CAIX-positive focinot shown).
revealed that they arose from more than one segment of the
nephron. No foci were evident in the thin limbs of the loop ofCellular morphology, site of origin,
Henle. Where a single CAIX-positive cell was seen, this wasand size distribution of lesions
almost always in the proximal tubule. In contrast, when fociImmunohistochemical identification of cells manifesting muta-
containing more than one cell were examined, they involvedtional dysregulation of the HIF/VHL pathway enabled further
distal tubules in almost all cases, although occasional multicellu-studies of the site, size, morphology, and staining patterns of
lar foci showed major morphological alterations such that thethese very early lesions. Examination of immunolabeled sections
tubular segment could not be determined with certainty. Toindicated that essentially all single cell profiles and the large
confirm the location of the multicellular foci within the nephron,majority of multicellular foci were not readily morphologically
serial sections were labeled for Tamm-Horsfall protein (uromod-distinguishable from surrounding tubular cells. To analyze the
morphological features of the multicellular foci in more detail, ulin), which is specifically expressed in the thick ascending limb
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Figure 4. Multicellular foci of CAIX immunoreac-
tivity involve distal tubules and show features of
clear cell RCC
Serial sections (A and C) or defined sections from
the series (B) were labeled for CAIX and other
antibodies or examined morphologically after
staining with hematoxylin and eosin.
A: Within a tubular profile, the cells labeling for
CAIX show a “clear cell” appearance.
B: A tubular profile that includes a focus of CAIX-
positive cells is seen to label with antibody to
Tamm-Horsfall protein (THP), showing that this is
a distal tubule. Note that the group of cells within
the profile which are labeled for CAIX do not
label for Tamm-Horsfall protein.
C: A distal tubule closely related to two glomeruli
is partly lined by CAIX-positive cells. These cells
are seen to express vimentin, which is not ex-
pressed by normal tubular epithelial cells, but is
seen in the glomerular mesangial cells.
(Final magnification: A: 420; B and C: 450).
of Henle’s loop and the early distal convoluted tubule (Sikri et always confined to single cell profiles over a substantial number
of identified lesions.al., 1981). This showed that multicellular foci occurred in tubular
profiles which labeled strongly for Tamm-Horsfall protein (Figure In order to gain insight into specific processes relevant to
tumor development, we next assessed vascularity in the region4B). However, we found that in these tubular profiles the cells
that expressed CAIX showed loss of Tamm-Horsfall protein of CAIX-positive foci and the proliferative index of the CAIX-
positive cells. We used an antibody to CD31 to label endothelialcompared to their neighbors (Figure 4B). This demonstrates that
loss of VHL function alters expression of a gene involved in cells and used CAIX labeling of adjacent sections to identify
CAIX-positive foci. We observed a substantial increase in thenormal distal tubular cell function. Conversely, when we exam-
ined the expression of vimentin, which is not expressed by extent of vascularization around tubules containing CAIX-posi-
tive cells (Figure 5A). These vessels also expressed laminin andnormal tubular epithelial cells, but is expressed by CCRCC
(Waldherr and Schwechheimer, 1985), we found that this was were strongly immunoreactive for CD34 (data not shown), thus
confirming that they were blood vessels and not lymphaticsexpressed in the CAIX-positive foci (Figure 4C).
To further analyze the size distribution of lesions arising in (Breiteneder-Geleff et al., 1999; Ezaki et al., 1990; Paal et al.,
1998). Quantitative analysis in two patients showed that CD31different parts of the nephron, we conducted a morphometric
analysis of sections derived from all eleven nephrectomy speci- labeling was directly contiguous with over 80% of the perimeter
of distal tubules containing CAIX-positive cells, irrespective ofmens. Altogether, 524 lesions could be classified as arising from
proximal or distal tubules based on the appearance of adjacent whether they displayed a normal or altered architecture (Figures
5A and 5B and data not shown). In contrast, CD31 labeling wascells in the tubular profile. We argued that any sustained net
proliferative advantage should lead to a geometric increase in only adjacent to approximately 25% of the basement membrane
of distal tubules that did not contain CAIX-positive cells (Figurethe number of cells in the lesion. Table 1 shows that in each
kidney, the size distribution of lesions arising in the distal neph- 5B). Equivalent results were obtained for CD34 (data not shown).
This marked increase in vascularization around CAIX-positiveron was compatible with such an effect, whereas the size distri-
bution for proximal tubules was strikingly different, being almost foci shows that they are promoting effective angiogenesis.
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Table 1. Distribution of focus size is different in proximal and distal tubules
Proximal tubule (number of cells) Distal tubule (number of cells)
Area
(mm2 ) 1 2–4 5–16 17–64 1 2–4 5–16 17–64 PT DT p
1 160 16 2 0 0 3 3 2 0 1.17 2.87 0.0083
2 232 33 0 0 0 0 3 5 3 1.00 14.27 0.00001
3 225 11 3 1 0 1 2 4 3 1.67 20.90 0.0006
4 321 37 5 2 0 6 9 6 3 1.43 7.87 0.00001
5 436 18 1 0 0 5 4 4 0 1.05 3.69 0.0004
6 134 10 3 0 0 25 12 15 4 1.31 4.77 0.0114
7 238 10 0 0 0 0 1 0 0 1.00 3.00 0.0044
8 28 10 0 0 0 0 2 4 0 1.00 6.50 0.0002
9 320 12 0 0 0 10 6 1 2 1.00 5.05 0.0067
10 80 86 6 0 0 6 16 12 5 1.06 6.61 0.00001
11 64 47 1 0 0 9 8 5 1 1.02 3.78 0.00001
Morphometric assessment of the CAIX-labeled foci was undertaken for each of the eleven nephrectomy specimens. The number of cells comprising each
focus was counted and the site of origin in the nephron assessed on the basis of tubular morphology. Each row contains data from one nephrectomy
specimen. Foci in distal tubules were generally multicellular. In contrast, those in proximal tubules almost exclusively contained a single CAIX-positive cell
in the plane of the section. PT and DT give the mean number of cells per focus in the proximal tubule and distal tubule, respectively, for each nephrectomy
specimen. The difference in the number of cells in distal and proximal tubular foci was statistically significant in each nephrectomy specimen (Wilcoxon
rank sum test).
To directly examine the rate of proliferation within the multi- case, 4/232 (1.72%) CAIX-positive cells were positive for Ki67
compared to 11/5196 (0.21%) distal tubular cells which werecellular foci of VHL inactivation in tubules that were morphologi-
cally near normal, we performed labeling experiments for the negative for CAIX, giving an 8.19-fold increase in Ki67 labeling.
In each case the difference in Ki67 labeling was highly statisti-proliferation-associated marker Ki67. In the two nephrectomy
specimens with the largest number of multicellular lesions, we cally significant (p  0.000123, 0.00164, respectively, using
Poisson approximation). We also assessed the rate of apoptosisassessed the Ki67 labeling index both in the multicellular CAIX-
positive foci and in distal tubules which were CAIX-negative. In using TUNEL labeling. Although some apoptotic cells were ob-
served in the regions of overt CCRCC, we did not find a singleone case, 5/210 (2.38%) CAIX-positive cells labeled for Ki67,
compared to 28/4964 (0.56%) distal tubular cells which were TUNEL-positive cell in the early multicellular lesions, and TUNEL
labeling was virtually absent in the CAIX-negative distal tubules.negative for CAIX, giving a 4.25 fold increase. In the second
Figure 5. Evidence that early lesions are angio-
genic
A: Serial sections were labeled with antibodies
to CAIX and CD31. Several tubular profiles are
seen to be lined by epithelial cells containing
CAIX. These tubular profiles are almost com-
pletely surrounded by CD31 immunolabeling, in
marked contrast to the other tubular profiles. A
glomerulus, G, is visible in the upper left part of
the field (Final magnification: 90).
B: Morphometric analysis of CD31 immunola-
beling in two nephrectomy specimens. The pro-
portion of the perimeter of selected tubular
profiles that was directly adjacent to CD31
immunolabeling was calculated. Tubular profiles
that contained CAIX-positive cells (red symbols;
right column in each panel) were more exten-
sively surrounded by CD31 immunolabeling than
tubular profiles in the same section that were
negative for CAIX (black symbols, left column).
The Wilcoxon rank sum test indicated a statisti-
cally significant difference in both specimens
(p  0.00001).
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Discussion keeper functions. For example, APC inactivation in the earliest
detectable lesions in colonic epithelium is associated with Ki67
labeling in virtually every cell (Shih et al., 2001). Furthermore,In this work we have demonstrated that the HIF pathway is
activated at a very early stage in the evolution of neoplastic when the size distribution of lesions was compared for foci that
could clearly be assigned as having a proximal versus distalkidney lesions in VHL disease. HIF upregulation in single cellular
profiles and concordant patterns of staining for HIF-1 and HIF origin, a striking difference was observed. Distal tubular lesions
manifest a range of size profiles with an approximate geometrictarget gene products in foci of VHL loss of function indicate
that activation of the HIF transcriptional response is either an size distribution, consistent with a net survival/proliferative ad-
vantage. In contrast, this was not observed for lesions sited inearly or an immediate consequence of VHL inactivation. Activa-
tion of HIF and target genes such as CA9 therefore provides a proximal tubules, which were essentially confined to single cells.
This indicates that the tumor suppressor mechanisms associ-robust system for the positive identification of early foci of VHL
inactivation, and an unusual opportunity to observe the steps ated with VHL are likely to be cell specific within the nephron.
In this respect, the distal tubule has some interesting attributes.that lead from apparently normal tubular epithelial cells to
CCRCC. First, cell turnover in this region under normal circumstances is
several fold greater than in the proximal tubule (Nouwen et al.,In the current study, this has provided several insights into
VHL-associated renal disease. First, it enabled the characteris- 1994). Second, in the normal kidney, expression of the mitogens
epidermal growth factor and transforming growth factor- istics of HIF pathway activation to be examined. For HIF-1 pro-
tein, progressively higher levels of immunoreactivity were ob- found in this region, but not in the proximal tubule (Hise et al.,
1996; Nouwen et al., 1994; Salido et al., 1989). Interestingly,served in morphologically normal foci, dysplastic foci, cystic
lesions, and CCRCC. With HIF-2, the protein was not detected TGF- expression is influenced by VHL status in fully trans-
formed RCC cells, which show growth dependence on the TGF-in the earliest foci, but staining of increasing intensity was pres-
ent in more advanced lesions. Although the difference in detec- /EGFR pathway (de Paulsen et al., 2001).
Since our studies are not sequential, they do not formallytion of HIF-1 and HIF-2 in the earliest foci could relate to
differences in the sensitivity of detection, studies of hypoxic “track” the origin of CCRCC. Indeed, the size distribution sug-
gests that the great majority of the smallest foci of VHL loss dorat kidney tissue indicate that HIF-1 is the isoform normally
activated by hypoxia in renal tubules, whereas HIF-2 is nor- not progress further. Nevertheless, that VHL loss appears to
lead to a proliferative advantage that is selective for the distalmally confined to nontubular cell populations (C. Rosenberger
and S.J.M., unpublished data). Thus, it is likely that VHL inactiva- tubule suggests that the associated tumors arise from this por-
tion of the nephron and not from the proximal tubule. Supportingtion leads to early or immediate upregulation of the normal
tubular cell isoform, HIF-1, with further events serving to am- this interpretation, in a recent preliminary report, mice with cell-
specific inactivation of VHL in the proximal tubule did not de-plify the response during progression to CCRCC. The influence
of different non-VHL oncogenic pathways on HIF activation has velop cysts or CCRCC (Haase et al., 2001). Other evidence on
the origin of CCRCC has been based on structural and markerbeen demonstrated in VHL competent tissue culture cells (for
reviews see Maxwell et al., 2001; Semenza, 2000). Our observa- protein expression studies of the cells in overt CCRCC, and
there have been proponents of a proximal tubular origin, a primi-tions indicate that multiple pathways may also influence the HIF
system in VHL defective native neoplastic lesions. tive stem cell origin, and a distal tubular origin (Motzer et al.,
1996). Absence of Tamm-Horsfall protein has previously beenSecond, the ability to identify very early phakomata within
otherwise normal tubular profiles enabled observations on the cited as a major piece of evidence against origin from the distal
tubule (Wallace and Nairn, 1972). However, our analysis of earlycharacteristics of these lesions. Mechanisms of tumor suppres-
sion have been divided into gatekeeping and caretaking func- foci within distal tubules showed a striking loss of Tamm-Horsfall
protein expression, indicating that this interpretation is mis-tions. Loss of a gatekeeping function leads directly to a net
proliferative advantage, whereas loss of a caretaker function leading.
An important challenge will be to elucidate the link betweenallows enhanced generation or survival of genetic mutations
that ultimately favor the emergence of clones with such an VHL loss-of-function and proliferation in distal tubular epithelial
cells and whether HIF activation is involved in this process. Inadvantage (Kinzler and Vogelstein, 1997). Though the tumor
suppressor mechanisms of VHL remain unclear, the gene prod- contrast to the current uncertainty of the link between VHL
inactivation and proliferation, the route to increased vascularityuct has been classified as a gatekeeper (Kondo and Kaelin,
2001). In keeping with this, reexpression in transformed renal can be reasonably attributed to HIF activation, which was re-
cently shown to be sufficient to promote increased formationcarcinoma cells has a major effect on growth as model tumors
(Iliopoulos et al., 1995). of competent blood vessels in normal skin (Elson et al., 2001).
What is intriguing is the activation of angiogenesis in these verySurprisingly, when all identified foci in the kidneys from VHL
patients were considered, we found a very low frequency of early lesions, in contrast to the usual position in solid tumors
where angiogenesis is a relatively late event in tumor evolutionmulticellular compared to single cell lesions, implying that any
advantage in terms of an overall increase in survival/proliferation (Hanahan and Folkman, 1996). One implication of this is that
these early lesions are likely to be unusually well oxygenatedrate over cell death is small in comparison with the rate of
mutational inactivation of VHL. When we examined the prolifera- compared to both normal tissues and other evolving solid tumors.
Finally, in addition to insights into tumorigenesis, identifica-tion rate in the multicellular foci of VHL inactivation, the labeling
index was 4- to 8-fold higher than we observed in control tubular tion of these premalignant lesions could be useful clinically.
First, a finding of CAIX-positive foci in the surrounding renalprofiles. This suggests that the early proliferative advantage
conveyed by VHL inactivation may be relatively modest com- parenchyma in surgical material from patients with sporadic
CCRCC might identify a small subset with a greatly increasedpared to other mutations in tumor suppressor genes with gate-
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Molecular genetic analysisrisk of developing further tumors who would benefit from spe-
DNA was extracted from microdissected cells using the Qiaquick DNA Minicific surveillance. Second, it may be possible to use the high
kit (Qiagen). PCR amplifications of microsatellite markers D3S1038 andlevel expression of CAIX on the cell surface to target premalig-
D3S1317 (see http://www.ncbi.nlm.nih.gov/entrez/ for primer sequences)
nant foci in patients with VHL germline mutations. were performed in 10 l reactions with 2 l DNA, 1 Taq DNA polymerase
buffer, 1.5 mM MgCl2, 0.5 U Thermoprime plus Taq Polymerase (ABgene),
Experimental procedures 200 M each dNTP and 2.0 pmol each primer. The forward primer was
labeled with a fluorescent dye (6-Fam for D3S1317 and Hex for D3S1038).
Clinical material After initial denaturation at 95C for 5 min, PCR was conducted for 35 cycles
Eleven nephrectomy specimens from ten VHL subjects were studied. Ne- of 95C for 30 s, annealing at 55C for 30 s, and extension at 72C for 30
phrectomies were performed at ages ranging from 26 to 53. One patient s, followed by a final extension for 5 min at 72C. PCR products were
had the second kidney removed two years after the first procedure. Each analyzed on an ABI 377 DNA analyzer. PCR product sizes were determined
kidney specimen included multiple cysts, as well as single or multiple solid by reference to an internal standard, and using Genescan v3.1.2 and Geno-
tumor lesions of the clear cell type. Specimens were formalin fixed and typer v2.5.2 software (Applied Biosystems).
embedded in paraffin wax.
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